Skyhawk Therapeutics expands licensing partnership with Biogen
Category: #health  By Paroma Bhattacharya  Date: 2019-07-09
  • share
  • Twitter
  • Facebook
  • LinkedIn

Skyhawk Therapeutics expands licensing partnership with Biogen

Skyhawk Therapeutics, Inc. has recently announced the expansion of its partnership with Biogen, which was initially announced on January 4, 2019.

The expansion, which leverages on the breadth of SkySTAR™ technology platform from Skyhawk, apparently expands the exclusive license of Biogen to global intellectual property rights beyond the original alliance’s research-stage therapeutic candidates for the treatment of conditions including spinal muscular atrophy, multiple sclerosis, and additional neurological disorders.

Sources familiar with the matter informed that under the agreement, Skyhawk would receive an upfront payment from Biogen and could benefit from potential future milestone royalties and payments.

According to chief executive officer and co-founder of Skyhawk, Bill Haney, Biogen has a compelling history of drug development across a multiple range of challenging conditions. The strong scientific culture of the company has already created a series of prominent global therapeutics and the work together till date has gone extremely well. Skyhawk would expand the opportunity to work together for helping more patients with challenging unmet medical requirements, Haney added.

For the uninitiated, Skyhawk Therapeutics is focused towards developing, discovering, and commercializing therapies that use its new SkySTAR™ platform to generate small molecule drugs that deliver advanced treatments to patients.

Sources further mentioned that Merck & Co. Inc., the USA based multinational pharmaceutical company, has reportedly selected Skyhawk Therapeutics for its proficiency in the development and discovery of small molecules which modulate RNA splicing. It has agreed to finance it up to $600 million for each program target along with royalties on sales of any commercialized products resulting from their partnership.

Seemingly, the agreement would be focused on potential treatments for cancer and certain neurological diseases. The agreement would mark the first external oncology partnership of Skyhawk following two years of work on its own internal oncology target, representing a careful move into the space for which it recruited new key talents.

Source Credits: https://www.prnewswire.com/news-releases/skyhawk-therapeutics-announces-expansion-of-collaboration-agreement-with-biogen-300880506.html

http://www.bioworld.com/content/skyhawk-lands-new-rna-focused-deal-merck



About Author

Paroma Bhattacharya

Email: [email protected]   

Paroma Bhattacharya

Paroma currently works as a content developer for Algosonline, MSF and a series of alike platforms. Fortified with a post-graduation degree in Journalism and Mass Communication, she delved head long into a writing career, creating resourceful and information enriched ...

Read More

More News By Paroma Bhattacharya

Mirati Therapeutics reveals Phase ½ results of KRAS inhibitor therapy
Mirati Therapeutics reveals Phase ½ results of KRAS inhibitor therapy
By Paroma Bhattacharya

Mirati Therapeutics, an oncology company that engages in the development of targeted therapies, recently released its clinical trial results for MRTX849. Reportedly, MRTX849 is a KRAS G12C inhibitor and the data from P...

Best Buy to offer free next-day delivery feature on various products
Best Buy to offer free next-day delivery feature on various products
By Paroma Bhattacharya

Online retailers are always launching new and attractive deals during the holiday season, as it grosses the highest sale time for the year. Several retailer rollout out attractive offers, such as discounts or complimen...

Nature Tech Corp partners with Aldevron for gene therapy manufacturing
Nature Tech Corp partners with Aldevron for gene therapy manufacturing
By Paroma Bhattacharya

The global cell and gene therapy sector is expected to witness a thriving period of growth over the forthcoming years. In fact, owing to the favorable growth conditions across the industry, numerous biotechnology and p...